“I think one of the problems is that we do run out of treatments in many of these patients at some point,” says William K. Oh, MD.
In this video, William K. Oh, MD, discusses how to best manage patients with oligometastatic prostate cancer, specifically stressing the importance of improving quality of life. These concepts stem from Oh’s presentation, which was given at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.